Another Cancer Treatment Startup for Merck

Merck & Co., Inc. (NYSE: MRK) has been busy this year. After securing a licensing deal with  Cocrystal (NASDAQ: COCP) for proprietary influenza A/B antiviral agents in January, the company found two biotechnology start-ups to bolster its cancer treatment portfolio. First, in February Merck bought Immune Design for $5.85 per share in cash, for an approximate value of […]